AbCellera (NASDAQ: ABCL) appoints Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer

Rhea-AI Filing Summary

AbCellera Biologics Inc. filed a report describing a leadership change in its medical organization. Sarah Noonberg, M.D., Ph.D., has been appointed as the company’s Chief Medical Officer, a key role overseeing medical strategy and clinical development. The company announced this appointment in a press release dated September 10, 2025, which is included as an exhibit to the report.

The filing classifies this as an "Other Event" and does not include financial results or transaction details. It confirms that AbCellera’s common shares trade on The Nasdaq Stock Market LLC under the symbol ABCL and that the report was signed by Chief Executive Officer Carl L. G. Hansen.

0001703057falseVancouverBC00017030572025-09-102025-09-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________

FORM 8-K

__________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 10, 2025

__________________________________________

AbCellera Biologics Inc.

(Exact name of registrant as specified in its charter)

__________________________________________

British Columbia			001-39781			Not Applicable
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification Number)

150 W 4th Avenue Vancouver, BC			V5Y 1G6
(Address of registrant’s principal executive office)			(Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

__________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o						Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o						Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o						Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o						Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common shares			ABCL			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Item 8.01    Other Events

On September 10, 2025, AbCellera Biologics Inc. (the “Company”), issued a press release announcing the appointment of Sarah Noonberg, M.D., Ph.D., as the Company’s Chief Medical Officer. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits

(d)Exhibits

Exhibit No.						Description
99.1						Press Release issued by AbCellera Biologics Inc. on September 10, 2025.
104						Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 10, 2025			ABCELLERA BIOLOGICS INC.
			By:			/s/ Carl L. G. Hansen
						Carl L. G. Hansen, Ph.D.
						Chief Executive Officer and Director (Principal Executive Officer)

FAQ

What did AbCellera Biologics Inc. (ABCL) disclose in this 8-K filing?

AbCellera Biologics Inc. disclosed that it appointed Sarah Noonberg, M.D., Ph.D., as its Chief Medical Officer and announced this change in a press release dated September 10, 2025, which is attached as an exhibit.

Which executive role was filled according to AbCellera (ABCL)'s 8-K?

The company reported the appointment of Sarah Noonberg, M.D., Ph.D., as its Chief Medical Officer, a senior position responsible for medical and clinical leadership.

When did AbCellera announce the Chief Medical Officer appointment?

The appointment of Sarah Noonberg as Chief Medical Officer was announced in a press release issued on September 10, 2025, the same date as the reported event.

Does this AbCellera (ABCL) 8-K include financial results or earnings data?

No. The report is limited to an Other Events disclosure related to an executive appointment and does not present financial results or earnings information.

What exhibits are attached to AbCellera’s 8-K about the CMO appointment?

The filing includes Exhibit 99.1, which is the press release announcing the Chief Medical Officer appointment, and Exhibit 104, the cover page interactive data file embedded as Inline XBRL.

On which exchange are AbCellera (ABCL) shares listed according to the filing?

The filing states that AbCellera’s common shares are listed on The Nasdaq Stock Market LLC under the trading symbol ABCL.